Jazz Pharma to pay $1B for rare disease drug co.

Jazz Pharmaceuticals PLC plans to buy drug maker Gentium SpA for roughly $1 billion in a cash deal aimed at expanding its rare disease drug portfolio.

http://www.biosciencetechnology.com/news/2013/12/jazz-pharma-pay-1b-rare-disease-drug-co